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Chapter 1:  Introduction to the Type III Secretion System 
 
 
 The type III secretion system (T3SS) has been identified as a critical factor for 
pathogenicity in more than twenty-five species of Gram-negative bacteria1, which cause 
disease in both plants and animals (including humans).2; 3  The resulting diseases are 
serious and potentially deadly, as exemplified by the recent European outbreak of the 
Shiga toxin-producing Escherichia coli (STEC).  This strain of E. coli, which causes 
systemic infection and essentially leads to kidney failure, has killed 21 individuals and 
infected more than 2400, making it the largest E. coli outbreak in recorded history 
(www.cdc.gov).  Outbreaks from other T3SS-harbouring bacteria have also been of 
recurrent concern for public health and safety, including those of Salmonella borne from 
contaminated vegetables in the United States.4  Others among the species that cause 
illness in humans are Pseudomonas aeruginosa, Yersinia spp., Burkholderia spp., and 
Shigella spp.  While several studies have indicated T3SS tip proteins as potential 
vaccination antigens, there are currently no approved vaccines for the pathogens listed 
above.5; 6  In addition, a number of these species are considered potential agents for 
bioterrorism, such as Burkholderia pseudomallei and Yersinia pestis.7  Despite the 
variance in infective strategies used by each of these species, they each use the T3SS to 
deliver bacterial effector proteins into their hosts to manipulate normal cellular function 
for bacterial advantage.  A better understanding of this system is necessary to eliminate 
the threat these species pose to public health.  
 The structural component of the TTSS, the type III secretion apparatus (T3SA), is 
the conduit by which secreted proteins of the T3SS are transported from the bacterial 
cytosol into a eukaryotic host (Figure 1-1).  This apparatus spans both the inner and outer 
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membranes of the bacteria as well as the host cell membrane.  Multiple copies of more 
than 25 proteins strictly coordinate the assembly of the apparatus and subsequent effector 
protein secretion, including those of the needle apparatus, translocon, chaperones, and 
many regulatory proteins.1; 2; 8  Each of these components are coded for in pathogenicity 
islands (PAIs), and while the organization within these pathogenicity islands is very 
similar between species, the resulting proteins exhibit differing levels of evolutionary 
divergence.9  
                      
            
	  
Figure	  1-­1.	  	  Generic	  illustration	  of	  the	  type	  III	  secretion	  system	  (T3SS)	  including	  the	  
needle	  apparatus,	  translocon,	  effector	  proteins,	  and	  chaperones.	  	  (Figure	  is	  from	  
reference	  5).	  	  The	  tip	  proteins	  and	  their	  respective	  chaperones	  involved	  in	  this	  
study	  are	  tabulated.	  
 
Following assembly of the needle apparatus and prior to effector secretion, 
intermediate activation steps involving translocon secretion and assembly have been 
proposed to involve environmental signaling.10; 11; 12  However, bacterial secretion 
becomes fully activated upon cell contact and effector proteins are then delivered to the 
cytosolic surface of the target cell.13; 14; 15  The roles of the secreted effectors vary widely 
Pathogen	   Tip	  Protein	   Chaperone	  
S.	  typhimurium	   SipD	   -­‐	  
S.	  flexneri	   IpaD	   -­‐	  
P.	  aeruginosa	   PcrV	   PcrG	  
Y.	  pestis	   LcrV	   LcrG	  
	  
	   3	  	  
among different species, but commonly bear a resemblance to eukaryotic factors in order 
to manipulate target signal transduction.2  Depending on the invading bacterial species, 
host responses to effector proteins can include actin cytoskeletal rearrangement and 
membrane ruffling (leading to bacterial intracellularization), altered vesicle trafficking, or 
evasion of the immune response by killing polymorphonuclear neutrophils and 
macrophages.13; 16; 17  Despite the divergence in effector types and in strategies for 
pathogenesis, many of the T3SS components are conserved both structurally and 
functionally between species. Increasing knowledge of T3SS assembly and regulation has 
permit developments of live vectors for exogenous antigen delivery using species such as 
S. typhimurium and P. aeruginosa.18; 19 
The tip protein, named for its localization to the needle tip (Figure 1-1), is a 
critical structural and functional component of the T3SS.20; 21  Relevant tip proteins 
discussed herein are SipD in Salmonella typhimurium, IpaD in Shigella flexneri, BipD in 
Burkholderia pseudomallei, PcrV in Pseudomonas aeruginosa, and LcrV in Yersinia 
Pestis.  In addition to their function in translocon assembly, tip proteins have been 
demonstrated to regulate secretion control in all species studied to date.22  This regulation 
is coordinated with chaperones in the bacterial cytosol and with external environmental 
cues.10; 11; 12  Structural studies of tip proteins and their binding partners are important in 
understanding T3SS-mediated infection and for potential drug design targeted at 
disrupting the assembly of the apparatus. 
 The contents of this thesis are focused on characterization of T3SS tip proteins 
and their binding partners.  The interaction of bile salts with SipD, the Salmonella tip 
protein, is described in chapter 2 (adapted from reference 13) along with a model for the 
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differential bile salt response between Salmonella and Shigella.  Chapter 3 is dedicated to 
structural characterization of PcrG in Pseudomonas aeruginosa and its binding 
interaction with the tip protein, PcrV.  Chapter 4 includes a discussion of the T3SS 
studies described in chapters 2 and 3 as well as the contribution of this work to the field.  
Finally, using the same experimental template applied in the biophysical characterization 
of the T3SS proteins, an addendum is included describing the interaction between 
proteins involved in SUMOylation.  These proteins are the Xenopus laevis E3 ligase, 
PIASy, and a SUMOylation target, PARP1. 
 All work described in this thesis, including experimentation and interpretation of 
results, is my own unless otherwise noted. 
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Chapter 2: Characterization of the Interaction of the Salmonella T3SS  
Protein SipD and Bile Salts 
 
 
INTRODUCTION  
 
 The type III secretion system (T3SS) is a complex and highly regulated scheme 
used by more than 25 Gram-negative bacteria for pathogenesis.1  Examples are the 
Salmonella spp. and Shigella spp., which utilize the T3SS to deliver effector proteins into 
the cytosol of human epithelial cells leading to actin cytoskeletal rearrangement, 
membrane ruffling, and bacterial internalization.2  Subsequent infection by these species 
results in dysentery (Shigella) or salmonellosis (Salmonella), each of which remain an 
ongoing problem in both developed and underdeveloped countries.   
A critical structural and functional component of the T3SS is the tip protein; 
named for its localization to the tip of the T3SS needle apparatus.3; 4  These tip proteins 
are known as SipD in Salmonella typhimurium, IpaD in Shigella flexneri, and BipD in 
Burkholderia pseudomallei and share a high degree of structural similarity in these 
species.  These species each require their respective tip proteins for translocon secretion 
regulation, assembly, and for subsequent pathogenesis.2; 5; 6  IpaD has recently been 
shown to interact with the small bile salts deoxycholate, taurodeoxycholate, and 
chenodeoxycholate7 ; each of these salts further stimulated T3SS activation by 
recruitment of translocon protein, IpaB, to the Shigella cell-surface.8  While SipD has 
also been shown to bind deoxycholate7, Salmonella exhibits the opposite response by 
repressing invasion via transcriptional downregulation.9; 10  
 Bile salts are a major component of bile and normally serve as a biological 
surfactant for absorption of fats and vitamins.11  Since bile salts are enriched in the 
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intestines11, they are thought to serve as a logical environmental cue for enteric 
pathogens.  However, it remains unclear why Salmonella and Shigella would have 
opposing responses to bile when IpaD12 and SipD13 crystal structures show such high 
similarity (Cα rmsd = 1.4Å).  Stensrud et. al7 previously used Förster Resonance Energy 
Transfer (FRET) analysis and computational docking simulations to predict a 
deoxycholate binding pocket in IpaD.  This binding pocket was proposed to be located 
between the IpaD central coiled coil and N-terminal two-helix bundle. 7  In the 
experiments presented here, NMR methods are used to identify residues of SipD 
interacting with bile salts deoxycholate, taurodeoxycholate, and chenodeoxycholate.  The 
results have identified a binding pocket distinct from that predicted for IpaD, which poses 
a potential rationale the opposing response of Salmonella and Shigella to bile salts.  Point 
mutations were also generated and tested for the ability of Salmonella to invade human 
epithelial cells.   
 
 
MATERIALS AND METHODS  
 
 
Protein Expression and Purification   
 
Wild-type S. typhimurium SipD (residues 39-343) was subcloned into pET-21a 
(Dr. Yu Wang, University of Kansas) to create a fusion with His6 and the Streptococcus 
GB1 domain at the N-terminus (cleavage of the appended tag with the Tobacco Etch 
Virus (TEV) protease resulted in an N-terminal “GHM” cloning artifact).  The construct 
was expressed in E. coli BL21(DE3) DNAY cells with 100 µg/mL carbenicillin and 30 
µg/mL kanamycin in all growth media.  Starter cultures were grown in 20 mL Luria-
Bertani (LB) media overnight at 37 °C followed by centrifugation at 4000 rpm.  
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Unlabeled SipD39-343 was grown by resuspending the starter culture in 1.0 L LB.  
Isotopically 15N-labeled SipD39-343 was acquired by resuspending the starter culture in 1.0 
L of M9 minimal media supplemented with 1.0 g/L 15NH4Cl.  Perdeuterated 13C,15N-
labeled SipD39-343 was prepared by resuspending the starter culture in the above media 
dissolved in 99% (v/v) D20 and supplemented with 2.0 g/L [13C]glucose instead of 
unlabeled glucose (Dr. Yu Wang, University of Kansas).  Cells were grown at 37 °C and 
induced with 1.0 mM isopropyl-β-D-thiogalactopyrandoside (IPTG) upon reaching A600 
~ 0.6-0.8.  Growth was continued overnight at 37 °C in a shaking incubator and cells 
were harvested by centrifugation.  Cells were then lysed by sonication, centrifuged 
(18200g, 10 min., 4 °C), and the supernatant was loaded onto a Ni2+-affinity column 
(Sigma).  Elutes from the Ni2+ affinity column containing the recombinant SipD were 
pooled and incubated with Tobacco Etch Virus (TEV)14 protease overnight.  The digested 
sample was loaded onto a Ni2+-affinity column, which retained the cleaved His6-GB1 tag 
and His6-tagged TEV protease while passing the cleaved GHM-SipD39-343.  Proteins 
samples were concentrated using Amicon Ultra 3K (Millipore) and protein concentration 
was determined using absorbance at 280 nm. 
 
15N Amino Acid Specific Labeling 
 
Eight different 15N-amino acid specifically labeled SipD39-343 constructs were 
expressed and purified to facilitate NMR assignments (Dr. Yu Wang, University of 
Kansas).  These included 15N-labeled Leu, Val, Ile, Ala, Phe, Tyr, Met, and Lys.  Each 
sample was prepared as previously described.15  Proteins were purified as described 
above. 
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Mutagenesis  
  
 Assignment of the four tryptophan side chain resonances of SipD (W135, W177, 
W234, and W290) was approached by introducing tyrosine point mutations using the 
QuikChange method (Stratagene).  The recombinant 15N-labelled SipD mutants were 
expressed and purified as described above. 
 Following NMR assignments, additional point mutations in SipD were designed 
based on the chemical shift perturbations resulting from bile salt titration.  Full length 
sipD was first subcloned into plasmid pRK216 and residues (S96, F109, S110, L116, 
F117, Q124, D131, E133, Y149, Q165, L179, V187, K188, V256, Q306, T307, and 
L322) were mutated to alanines using the QuikChange method (Stratagene).  Alanine 
substitutions were chosen to minimize changes in protein folding.  All mutations were 
confirmed by DNA sequencing.   
 
NMR Spectroscopy 
 
NMR data were acquired at 30 °C with a Bruker Avance 800 MHz spectrometer 
equipped with a cryoprobe, processed with NMRPipe17, and analyzed with NMRView18.  
Before NMR data collection, purified protein samples were dialyzed into NMR buffer 
(10 mM sodium phosphate, pH 6.5, 10 mM NaCl, and 10% (v/v) D2O).  Backbone 
assignments were achieved using 0.5 mM perdeuterated 15N,13C-SipD39-343 to collect two-
dimensional 1H-15N TROSY-HSQC19 as well as three-dimensional TROSY-HNCA20, 
TROSY-HNCACB21, TROSY-HNCO21, and TROSY-HN(CA)CO21 (Dr. Yu Wang, 
University of Kansas).  Two-dimensional 1H-15N TROSY-HSQC19 were also collected 
for each 15N-amino acid-specifically labeled sample.  To assign tryptophan side chains, 
2D 1H-15N HSQC or 1H-15N TROSY-HSQC19 were collected for 15N-labeled SipD39-343 
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W135Y, W177Y, W234Y, and W290Y.  For NMR chemical shift mapping, 2D 1H-15N 
TROSY-HSQC19 were collected using 15N-SipD39-343 titrated with increasing 
concentrations of deoxycholate (Amresco), chenodeoxycholate (Sigma), 
taurodeoxycholate (Sigma), or cholate hydrate (Sigma).  Samples were prepared as 
follows:  0.6 mM 15N-SipD39-243 was dialyzed overnight into 1.0 L NMR buffer 
containing increasing concentrations of deoxycholate (0.0, 0.7, 1.4, or 2.1 mM) or 
chenodeoxycholate (0.0, 0.3, 0.6, 1.3, or 2.6 mM) and 0.7 mM 15N-SipD39-343 in 1.0 L 
NMR buffer with taurodeoxycholate (0.0, 0.3, 0.7, 1.3, 2.6 mM) or cholate hydrate (0.0, 
0.3, 0.7, 1.3, or 2.6 mM). 
 
Isothermal Titration Calorimetry (ITC)   
 
Microcalorimetric titrations were performed under isothermal conditions at 25 °C 
or 37 °C using a VP-ITC instrument (MicroCal Inc., Northampton, Ma, USA). Titrations 
were carried out under a range of buffering conditions, which tested varied salt 
concentration (10-100 mM NaCl), buffering reagents (Tris/HCl and phosphate buffer), as 
well as pH (6.5-8.0).  The calorimetric cell (volume 1.4 mL) was loaded with 380 µM 
unlabeled SipD39-343 and was titrated with small volumes (10 µL) of 2.5 mM 
deoxycholate for a total of 24-29 injections.  Injections of 2.5 mM deoxycholate into 
buffer alone served as a control.  Each injection was added at 5.0 µL/s with 240 s spacing 
to return the differential power to baseline.  The cell was stirred throughout the procedure 
by constant rotation of the injection syringe at 310 rpm.  Automated injections from a 
computer controlled syringe into the adiabatic Hastelloy® shield allowed highly sensitive 
measurements (0.1 ucal) of heat exchange.  Raw data was analyzed using Origin 7.0 
software (MicroCal Inc.). 
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Salmonella Invasion Assay 
 
The effect of the sipD point mutations on the ability of S. typhimurium to invade 
human epithelial cells was assessed using a modified gentamicin protection invasion 
assay.22  The chosen line of cultured human epithelial cells was Henle 407 (American 
Type Culture Collection # CCL-6).  Wild-type S. typhimurium (SL1344) was provided by 
Dr. Bradley Jones (University of Iowa) and a sipD knockout strain (sipD-) was prepared 
as previously described.13  The pRK2-sipD plasmids with either wild-type or mutant sipD 
were electroporated into the S. typhimurium sipD- strain and transformants were selected 
for trimethoprim resistance.  Single colonies were inoculated into 10 mL LB 
supplemented with 25 mg/L trimethoprim, 50 mg/L ampicillin, and 50 mg/L 
chloramphenicol and grown at 37 °C overnight without aeration.  Overnight cultures 
were diluted 1:10 in LB containing 1.0 mM IPTG +/- 2.0 mM deoxycholate and 
incubated at 37 °C without aeration for 3-3.5 hours (until O.D. ~0.6).  Approximately 15 
µL of the bacterial suspensions were added to the Henle 407 cells which had previously 
been grown to confluence in Dulbecco’s Modified Eagle’s Medium (DMEM) and 10% 
fetal bovine serum at 37 °C with 5% CO2 in 24-well plates.  Invasion progressed for 60 
min at 37 °C in a 5% CO2 chamber before the suspension was aspirated and washed 3× 
with DMEM containing 100 mg/mL gentamicin.  The Henle 407 cells were then 
incubated in the DMEM-gentamicin solution for 90 min, aspirated, washed 1× with 
DMEM, and lysed with 1% Triton X-100 to release the internalized Salmonella.  The 
number of resulting colonies, which correlate to invasiveness, was estimated by a serial 
dilution of the lysate followed by plating.  All invasion assays were performed in 
triplicate. 
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RESULTS 
 
 
Protein Expression and Purification 
 
NMR experiments were initially performed using full length SipD1-343 and the 
resulting HSQC spectra were of poor quality.  However, it has been previously shown 
that homologous tip proteins are disordered at the amino terminus.  Crystal structures of 
IpaD and BipD lacked electron density below residues 39 and 35, respectively.12  
Therefore, recombinant SipD39-343 was expressed with a His6-tagged GB1 domain fused 
to the N-terminus, purified using Ni2+ affinity chromatography, and digested with TEV 
protease to remove all but a three-residue N-terminal cloning artifact, GHM.  Circular 
dichroism and thermal denaturation data showed that the recombinant SipD remained 
highly α-helical and maintained the core structure of SipD.  Subsequently, HSQC data 
(acquired by Dr. Yu Wang, University of Kansas) for the truncated SipD revealed well-
dispersed spectra, contrary to that of the full length protein (data not shown). 
 
NMR Assignment 
  
The 2D 1H-15N HSQC spectrum of recombinant SipD39-343 was assigned nearly to 
completion using perdeuteration, TROSY NMR, and 15N-amino acid-specific labeling 
(Dr. Yu Wang, University of Kansas).  These experiments permitted identification of 274 
of 295 non-proline backbone resonances; the remaining could not be assigned due to 
peak overlapping or broadening.  In addition to backbone assignments, the side chains of 
all four tryptophan residues (W135, W177, W234, and W290) were assigned by 
individually mutating to tyrosines.  Resulting changes in the overall TROSY and HSQC 
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spectra were minimal, which suggested limited folding changes and permitted side chain 
assignments (Figure 2-1).   
 
 
Figure 2-1.  Sampling of the proton-nitrogen correlation spectra of wild-type SipD39-343 
and the four SipD39-343 mutants W135Y, W177Y, W234Y, and W290Y.  Both (A) 2D 1H-
15N TROSY and (B) 2D 1H-15N HSQC spectra were used to assign the tryptophan side 
chains. 
 
Despite the challenge in assigning all residues, 93% of the backbone Cα, Cβ, and 
C’ resonances were assigned and thereby permit the calculation of secondary Cα, Cβ, and 
C’ chemical shifts (Figure 2-2).  The resulting secondary chemical shift data indicated a 
primarily α-helical secondary structure with several short β strands.  In fact, the 
secondary structure of the recently obtained crystal13 of SipD39-343 corresponds very well 
with that predicted from the NMR secondary chemical shifts.  This similarity suggests 
that the truncated protein exhibits little difference in 3D structure when in solution.  
Additionally, secondary structure alignment of the SipD13 and IpaD12 crystal structures 
reveal only minor variation in α-helix and β strand lengths and spacing between the two 
tip proteins (Figure 2-3).   
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Figure 2-2.  NMR secondary chemical shifts of Cα (A), Cβ (B), and C’ (C) of SipD39-343 
shown along with the secondary structures from the SipD39-343 crystal (top).  Secondary 
structure is denoted with solid lines (loops), wavy lines (helices), a dotted line 
(disordered loop), and arrows (β strand).      
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Figure 2-3.  Sequences alignments of tip proteins SipD, IpaD, and BipD along with the 
secondary structures of IpaD12 (PDB 2J0O) and SipD13 (PDB 3NZZ) crystal structures.  
Secondary structures are representative of a composite of the asymmetric units from each 
protein.  The sequences were aligned using ClustalW24 and the figure was made using 
ESPript25 by Dr. Yu Wang, University of Kansas. 
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NMR Titrations 
 
NMR was used to identify the binding site on SipD39-343 for bile salts 
(deoxycholate, taurodoxycholate, chenodeoxycholate, and cholate hydrate).  Purified 15N-
SipD39-343 was dialyzed into increasing concentrations of each bile salt followed by 
acquisition of 2D 1H-15N TROSY spectra at each bile concentration.  The maximum 
ratios between bile salt and protein were limited by the critical micelle concentration 
(CMC) of each bile salt and by the high protein concentration requirement for quality 
NMR data.  The bile salt CMCs were 5 mM, 2.5 mM, 7 mM, and 18 mM for 
deoxycholate25, taurodeoxycholate26, chenodeoxycholate25, and cholate hydrate25, 
respectively.   
After superimposing the 2D 1H-15N TROSY spectra at each bile salt 
concentration, all but the cholate hydrate (Figure 2-7) proved to specifically interact with 
SipD39-343.  Upon titration with increasing quantities of deoxycholate (Figure 2-4), 
taurodeoxycholate (Figure 2-5), and chenodeoxycholate (Figure 2-6), many of the SipD39-
343 residues experienced gradual chemical shift changes suggesting an interaction in the 
fast-exchange NMR time scale.  For each titration, all residues experiencing a change in 
chemical shift were categorized as strongly perturbed (ΔδHN > 0.05ppm) or significantly 
perturbed (0.03ppm < ΔδHN < 0.05ppm) based on the extent of peak migration. 
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 A. 
 
 B. 
 
 
Figure 2-4. (A) The four overlaid 2D 1H-15N TROSY spectra of 15N-SipD39-343 titrated 
with increasing deoxycholate-protein ratios.  An insert of the deoxycholate molecular 
structure is included, several of the affected residues are boxed with their assignment, and 
noise peaks are acknowledged (*). (B) An expanded view of perturbed residues including 
arrows to denote the direction of peak migration.   
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 B. 
 
 
Figure 2-5. (A) The four overlaid 2D 1H-15N TROSY spectra of 15N-SipD39-343 titrated 
with increasing taurodeoxycholate-protein ratios.  An insert of the taurodeoxycholate 
molecular structure is included and several of the affected residues are boxed with their 
assignment. (B) An expanded view of perturbed residues including arrows to denote the 
direction of peak migration.   
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Figure 2-6. (A) The four overlaid 2D 1H-15N TROSY spectra of 15N-SipD39-343 titrated 
with increasing chenodeoxycholate-protein ratios.  An insert of the chenodeoxycholate 
molecular structure is included and several of the affected residues are boxed with their 
assignment. (B) An expanded view of perturbed residues including arrows to denote the 
direction of peak migration. 
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 A. 
 
 B. 
 
 
Figure 2-7. (A) The four overlaid 2D 1H-15N TROSY spectra of 15N-SipD39-343 titrated 
with increasing cholate hydrate-protein ratios.  An insert of the cholate hydrate molecular 
structure is included and several of the affected residues are boxed with their assignment. 
(B) An expanded view for comparison with perturbed residues in Figures 2-4, 2-5, and 2-
6. 
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Figure 2-8.  Weighted chemical shift differences (ΔδHN) of SipD39-343 upon final 
titrations with deoxycholate (A), taurodeoxycholate (B), and chenodeoxycholate (C) 
(ΔδHN = [1/2(δH2 + 1/25δN2)]1/2 (27)).   The average ΔδHN of the deoxycholate titration was 
0.011 ppm with a standard deviation (σ) of 0.011 ppm.  Any ΔδHN value more than 2σ 
greater than the average (or 0.033 ppm) regarded as significant.  Horizontal lines (drawn 
at ΔδHN = 0.03 ppm) illustrate this distinction.   
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After quantifying the ΔδHN for each residue in the SipD39-343 sequence, the 
interaction profiles for the bile salts appeared very similar (excluding that of cholate 
hydrate).  Deoxycholate produced the greatest chemical shift changes and the residues 
most strongly perturbed (ΔδHN > 0.05ppm) were S110, A111, L116, F117, Y149, L179, 
V187, K188, and T309 (Figure 2-8A).  Other significantly perturbed residues (0.05ppm > 
ΔδHN > 0.03ppm) included A58, Q63, L87, F109, and S114 (Figure 2-8A).  Residues 
strongly perturbed by taurodeoxycholate (ΔδHN > 0.05ppm) were similar to those from 
deoxycholate with the addition of E133 and the exception of T309 (Figure 2-8B).  
Taurodeoxycholate also significantly perturbed (0.05ppm > ΔδHN > 0.03ppm) residues 
E70, S96, F109, A115, L150, Y312, and L318 (Figure 2-8B).  Finally, while 
chenodeoxycholate produced an interaction profile similar to that of deoxycholate and 
taurodeoxycholate, its effects on chemical shift changes were much less intense.  
Chenodeoxycholate produced strong perturbations (ΔδHN > 0.05ppm) on residues S110, 
A111, and F117 and significantly perturbed (0.05ppm > ΔδHN > 0.03ppm) residues Y149, 
T161, L179, V187, and K188 (Figure 2-8C).  
 
Using the published crystal structure of SipD39-343, residues that were strongly 
perturbed cluster into two regions of the protein (Figure 2-9).  The larger of these clusters 
sits primarily in the loop between residues 110 and 134 and also includes the proximal 
Y149 on helix α4 and the W234 side chain (deoxycholate and chenodeoxycholate only) 
on helix α6.  The smaller strongly perturbed cluster sits distally in β strands β1 and β2.  
Finally, a set of minor perturbations occurs in the N-terminal 2-helix bundle including 
A58, Q63, and L87 (deoxycholate only) as well as E70 and S96 (chenodeoxycholate 
only).   
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Figure 2-9.  Ribbon illustration of the SipD crystal structure.13  Residues with significant 
chemical shift changes (ΔδHN > 0.03ppm) from deoxycholate titrations are depicted in red 
and the corresponding region of binding in IpaD is represented as a black oval (as 
predicted by computer docking).  Ribbon coloration illustrates the N-terminal to C-
terminal transition. 
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Isothermal Titration Microcalorimetry 
 
The protein and bile salt concentrations used in the microcalorimetric experiments 
were based on the CMC limitations of deoxycholate as well as the “experimental K 
window” (Figure 2-11) that would permit accurate KD calculations.  To avoid significant 
heat exchange from micelle disruption as the concentrated salt was injected and diluted in 
the adiabatic cell, the injection syringe was loaded with 2.5 mM deoxycholate (ca. half of 
the reported CMC26).  Figures 2-10a and 2-10b illustrate a control titration performed by 
injecting deoxycholate into buffer alone (100 mM NaCl, 20 mM NaHPO4, pH 7.5).  
While the starting bile salt concentration was below the reported CMC, there was still an 
appreciable quantity of heat absorbed (~7 kcal/mol) by initial injections, suggesting that 
even 2.5 mM deoxycholate retains a small number of micelles that dissociate upon 
injection.  Since the KD of the SipD39-343-deoxycholate interaction has been reported 
(using fluorescence polarization) to be in the micromolar range7, the critical parameter c 
of the isotherm was already in the low end of the experimental K window (Figure 2-11).  
Therefore, the background heat exchanged from micelle dissociation could not be further 
reduced by using lower concentrations of deoxycholate.  Figure 2-12 illustrates the 
resulting isotherm from a titration of 380 μM	  SipD39-343 with 2.5 mM deoxycholate.  The 
heat exchanged from interaction of the tip protein and bile salt clearly does not outweigh 
that of the micelle dissociation.  Combined, these two events convolute the calorimetric 
titration curve, which does not resemble a typical isotherm.  Subtracting the heat 
absorbed by micelle dissociation from each injection, Figure 2-13 shows the contribution 
of SipD39-343-deoxycholate binding to the overall isotherm.  The curve could not be fit to 
a one- or two-site binding model (chi2>4500).  Additional trials testing other salt 
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concentrations, pH, buffers, and DTT (10 mM NaCl, 10 mM NaHPO4, pH 7.0; 100 mM 
NaCl, 20 mM Tris/HCl, pH 8.0; 100 mM NaCl, 1.0 mM DTT, 20 mM NaHPO4, pH 7.5) 
resulted in very small heat exchange that could not be fit to one-site or two-site models 
(data not shown).  Thus, ITC is not a useful method to determine the SipD-bile 
interaction. 
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Figure 2-10.  (A) Raw data from a series of 25 10µL injections of 2.5mM deoxycholate 
into buffer at 25°C.  (B) Titration curve based on integration of raw injection heats with 
respect to time. 
 
 
 
    c = KMtotn 
 
    K -  binding association constant 
    Mtot –  initial macromolecule concentration 
    n -  stoichiometric ratio 
 
Figure 2-11.  The experimental K window (VP-ITC User’s Manual, MicroCal) illustrates 
the range of the unitless constant c permitting ideal measurement of the binding 
association constant KA.  Ideal isotherms for KD approximation have a value of c between 
5 and 500 (VP-ITC User’s Manual, MicroCal). 
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Figure 2-12.  (A) Raw data from 10µL injections of 2.5mM deoxycholate into 380µM 
SipD39-343 at 25°C.  (B) Titration curve based on integration of raw injection heats with 
respect to time without subtracting background heat of micelle dissociation. 
 
 
 
 
Figure 2-13.  Integrated curve of SipD39-343 titrated	  with	  2.5	  mM	  deoxycholate	  after	  
subtraction	  of	  background	  heat	  from	  micelle	  dissociation. 
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Salmonella Invasion Assay 
 
To identify SipD residues that may be important for bacterial invasion or 
interaction with bile salts, a Salmonella invasion assay was used to assess the ability of 
SipD mutants to invade cultured human intestinal epithelial cells.  A set of alanine point 
mutations of SipD were designed at residues strongly perturbed by NMR titrations with 
deoxycholate or significantly perturbed by more than one bile salt.  These included 
perturbed residues on or proximal to the 110-134 loop, on the distal β1 and β2 strands, 
and others (shown in Figure 2-14).  Relative percent invasion was determined with 
reference to the SipD-rescued strain in the absence of deoxycholate.  Wild-type and 
SipD-rescued (sipD+) strains of Salmonella both showed decreased invasiveness when 
incubated in the presence of deoxycholate.  Of the 15 tested mutants, only 2 (L116A and 
Y149A) were found to maintain similar invasiveness in the presence and absence of 
deoxycholate (within 1 standard deviation).  However, as in the case of all but 5 
mutations, the L116A and Y149A exhibited reduced invasion levels in comparison to the 
referenced SipD-rescue.  Therefore, while these 2 alanine substitutions may have 
abolished a deoxycholate binding site, residues L116 and Y149 may also play another 
functional role in Salmonella invasion.  On the other hand, the 5 previously mentioned 
mutations (S96A, S110A, F117A, Q165A, and V256A) that had no effect on invasion 
efficiency in deoxycholate absence and failed to abolish deoxycholate mediated invasion 
reduction are likely of less functional significance. 
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Figure 2-14.  Results from the Salmonella invasion assay (legend: WT, wild-type strain 
SL1344, sipD-, sipD null strain; sipD+, wild-type sipD from plasmid pRK2-sipD 
introduced into null strain; S96A, F109A, S110A, L116A, F117A, D131A, Y149A, 
Q165A, L179A, Q165A, L179A, V187A, K188A, V256A, Q306A, T307A, and L322A 
are single point mutants of pRK2-sipD introduced into the null strain.  Bar color indicates 
the presence or absence of deoxycholate (DOC) in the bacterial culture incubation step.  
Mutants of residues strongly perturbed in the NMR titration with DOC are indicated (*). 
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DISCUSSION  
 
 While previous studies have indicated that Salmonella and Shigella have opposing 
responses to bile salt exposure7-10, a model detailing the differing mechanism of 
regulation remains unclear.  Others have proposed that bile salts initiate a T3SS 
transcriptional repression cascade in Salmonella through the SirA-BarA two-component 
system9, however Stensrud et. al7 have shown that Salmonella and Shigella interact 
directly with deoxycholate with their respective tip-proteins, SipD and IpaD.  While a 
deoxycholate binding site for IpaD has been proposed via computer docking7, this study 
provides the first experimental identification of a bile salt binding site in SipD.  This is 
also the first case of successful NMR characterization of a T3SS tip protein, which was 
previously impeded due to the large number of residues, poor solubility in NMR buffer, 
and disordered termini common to tip proteins.  Based on the apparent disorder of 
homologous regions of BipD12; 28 and IpaD12 crystals, a 38-residue truncation from the 
SipD N-terminus was constructed and provided an excellent NMR spectrum for 
assignment.  Nearly all of the SipD39-343 backbone amide peaks were assigned using 
perdeuteration, TROSY, and amino acid-specific labeling.  These included all of the 
backbone peaks showing changes in chemical shifts from the bile salt titrations (Figures 
2-4, 2-5, and 2-6). The tryptophan side-chain peaks were also assigned, including W234 
which was perturbed by deoxycholate and taurodeoxycholate, by individual tyrosine 
substitutions. 
 After mapping the residues perturbed by bile salts on the crystal structure of 
SipD39-343 (Figure 2-9), a majority of the residues strongly perturbed by deoxycholate, 
taurodeoxycholate, and chenodeoxycholate were found in two clusters.  The minor 
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cluster, albeit much smaller, is located in the β1 (L179) and β2 (V187 and K188) strands.  
The major cluster is found far from the minor cluster in the 110-134 loop (S110, A111, 
L116, F117) or facing the loop in the α4 (Y149) or α6 (W234-sc) helices.  These NMR 
results suggest that the primary bile salt binding site in SipD sits between the 110-134 
loop and the central coiled coil.  Chemical shift changes in the distal β1 and β2 strands 
are likely due to small conformational changes or nonspecific interaction.  In comparison 
to a previous study of the bile salt binding pocket in the homologous Shigella tip protein, 
IpaD7, the proposed binding site in SipD is oriented on the opposite side of the central 
coiled-coil.  Stensrud et. al7 used two approaches to model deoxycholate binding in IpaD.  
FRET analysis suggested binding near the midpoint of the oblong protein and computer 
simulated binding (Autodock) identified a binding pocket between the N-terminal two-
helix bundle and the central coiled coil.  While the NMR proposed binding pocket for 
SipD also lies near the midpoint of the central coiled coil, there were no strong chemical 
shift changes in the region homologous to the proposed IpaD binding site.  Only four 
residues in helices α1, α2, and α8 (A58, Q63, L87, and T309) were perturbed by 
deoxycholate titrations, however to a much less extent as that seen in the primary cluster.   
To further examine the functional role of SipD39-343 residues perturbed by NMR 
titrations, a Salmonella invasion assay was designed to identify mutants that could 
maintain wild-type invasion efficiency while abolishing deoxycholate binding.  None of 
the mutants were able to fit both criterion, however, two mutants (L116A and Y149A) 
showed similar invasion levels in the presence and absence of deoxycholate.  These 
residues both reside in the primary cluster of residues perturbed by NMR titrations with 
deoxycholate and in close proximity to one another.  The remainder of the mutants tested, 
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including those in the region equivalent to the predicted deoxycholate binding site of 
IpaD, were unable to abolish deoxycholate mediated invasion reduction.  Based on these 
observations (in combination with NMR titration results), it was concluded that SipD and 
IpaD interact with bile salts at different surfaces, despite strong similarity in their tertiary 
structures (Cα rmsd = 1.4 Å) (Figure 2-3). We propose that differences in bile salt 
binding between SipD and IpaD hold a causal relationship with the different responses of 
Salmonella and Shigella to bile salts.  Both of these tip proteins have been shown to be 
present at the bacterial surface prior to host cell contact and hold a logical position for an 
environmental sensor.4; 30  
Despite the successful identification of a bile salt binding site in SipD39-343, the 
use of truncated SipD thwarted an analysis of bile salt interaction with the N-terminal 38 
residues.  However, the importance of this N-terminal region has previously been 
attributed to its necessity for secretion of SipD through the T3SS needle.31; 32  Another 
limitation in the experiments herein was the inability to determine the KD of the SipD39-
343 interaction with bile salts by means of ITC or NMR titrations due to the CMCs of bile 
salts.  For ITC, the deoxycholate concentration in the injection syringe could not be 
reduced below the threshold for micelle formation without affecting the accuracy of KD 
estimation from the isotherm.  With two distinct processes occurring in the adiabatic cell 
(SipD-deoxycholate and micelle disruption), it is clear why the resulting isotherm appears 
convoluted.   
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Chapter 3:  PcrG is a Partially Structured Protein 
 
 
INTRODUCTION 
 
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that is most 
frequently associated with nosocomial infections in patients with cystic fibrosis, AIDS, 
cancer, or other ailments that compromise the immune system.1  To initiate infection, P. 
aeruginosa utilizes the type III secretion system (T3SS) to inject effector proteins into 
host cells.2  Four of these effector proteins have been identified (ExoT/U/S/Y)3 and have 
been shown to effectively evade primary immune response by destroying macrophages 
and polymorphonuclear neutrophils (PMNs)4.  In fact, the simple assembly of the T3SS 
translocon in these cells has been demonstrated to perforate cell membranes sufficiently 
for oncotic cell death.5  Two proteins that have been discovered to play critical roles in 
assembly and regulation of the T3SS apparatus in P. aeruginosa are the tip protein, PcrV, 
and its proposed chaperone, PcrG.6; 7     
Effector proteins in P. aeruginosa are not secreted until induced by either cell 
contact or calcium depletion.4  Using a  β-galactosidase assay, Lee et. al8 demonstrated 
that deletion of either PcrG or PcrV results in constitutive effector secretion, even in the 
absence of calcium depletion or cell contact, and that the effect of these deletions is 
additive.  In the same study, PcrV export and assembly at the needle tip was shown to be 
critical for effector secretion regulation and the presence of PcrG is required for efficient 
PcrV secretion.  Results from several labs have confirmed that PcrG and PcrV directly 
interact9; 10, however, a point mutant disrupting this interaction revealed that secretion 
control is still maintained8.  Therefore, a model has been proposed where PcrG plays a 
role in facilitating PcrV secretion, but also holds a role in effector secretion regulation 
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that is independent of PcrV-binding.  This model is notably different from the current 
model for the highly sequentially related homologs in the Yersinia T3SS (LcrG and LcrV, 
respectively).11 
 Two unique LcrV binding domains on LcrG have been separately proposed by 
yeast two-hybrid studies12 and NMR chemical shift mapping13.  One aim of this study 
was to identify whether the PcrV binding domain on PcrG is conserved with previously 
proposed LcrV binding domains on LcrG.  Instead, NMR chemical shift mapping 
suggested that PcrV induces a global change in PcrG structure that likely results as a 
combination of PcrV-binding interactions and binding-induced conformational changes.  
In addition, the first experimentally derived information on sequence specific secondary 
structure identified the regions of PcrG that adopt either α–helical or random coil 
conformation.           
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MATERIALS AND METHODS 
 
 
Protein Expression and Purification 
 
Two constructs of wild-type P. aeruginosa PcrG (full length and residues 9-76) 
were PCR amplified from cDNA and subcloned into a pET-21a expression vector with a 
C-terminal fusion to a TEV protease cleavage site and His6-tagged GB1 domain.  
Resulting plasmids were expressed in BL21(DE3)-DNAY competent E. coli cells as 
follows: Recently transformed cells were grown in 10 mL starter cultures of LB media 
overnight at 37 °C followed by centrifugation at 4000 rpm.  For unlabeled protein, cell 
pellets were resuspended in 1.0 L LB; whereas isotopically labeled protein (15N,13C and 
15N) was attained by resuspension into 1.0 L M9 minimal media supplemented with 2.0 
g/L 13C D-glucose and/or 1.0 g/L 15NH4Cl.  All media contained 30 µg/mL kanamycin 
and 100 µg/mL carbenicillin.  Cells were then incubated at 37 °C, induced with 1.0 mM 
isopropyl-β-D-thiogalactopyrandoside (IPTG) at an O.D. of ~0.8, and cell growth was 
continued overnight at 15°C with aeration to a final O.D. of ~2.5.  Cells were harvested 
by centrifugation, resuspended in binding buffer (500 mM NaCl, 20 mM Tris-HCl, 5 mM 
imidazole, pH 8.0), and lysed by sonication in the presence of 10 mg phenylmethyl 
sulfonyl fluoride (PMSF).  The lysate was centrifuged again to remove cell debris and the 
supernatant was loaded onto a Ni2+-affinity column.  The Ni2+-affinity column was 
washed with binding buffer and eluted with 250 mM imidazole.  For NMR and CD 
spectroscopy application, pooled elutes were digested with recombinant Tobacco Etch 
Virus (TEV) protease14 and a second Ni2+-affinity purification as described15.  Cleavage 
with TEV protease resulted in a C-terminal cloning artifact (-GSENLYFQ).  Protein was 
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concentrated using Amicon Ultra 3K (Millipore) and concentration was determined by 
the Bradford method. 
 Wild-type P. aeruginosa PcrV (residues 25-294) was subcloned into a pET-21a 
expression vector with an N-terminal His6-tagged GB1 domain fusion.  The N-terminal 
24 residues of PcrV were truncated based on the apparent disorder of the homologous 
region in the LcrV crystal structure22.  Unlabeled protein was expressed and purified as 
described above including TEV proteolysis.  TEV cleavage of the PcrV25-294 construct 
resulted in an N-terminal cloning artifact (GHM-). 
 
NMR Spectroscopy 
 
NMR data were collected at 25°C using a Bruker Avance 800 MHz (at the 
University of Kansas) and a Varian 900 MHz (at the Rocky Mountain Regional 900 MHz 
NMR Facility, University of Colorado) spectrophotometer equipped with a cryoprobe, 
processed with NMRPipe16, and analyzed using NMRView17.  All protein samples were 
dialyzed overnight in NMR buffer (10 mM NaHPO4, 10 mM NaCl, 10% (v/v) D2O, pH 
7.0).  15N-PcrGFL (0.8 mM) and truncated 15N-PcrG9-76 (0.7 mM) were used to acquire 
initial 2D 1H-15N HSQC spectra18.  For assignment of the 15N-PcrG9-76 carbon backbone, 
0.6 mM 15N,13C-PcrG9-76 was used to collect 2D 1H-15N HSQC, 3D HNCA, 3D 
HNCACB, and 3D CBCA(CO)NH.18; 19; 20  Secondary structure was determined using the 
secondary chemical shifts of Cα, Cβ, and C’.21  For NMR chemical shift mapping, 2D 1H-
15N HSQC spectra18 were acquired for 15N-PcrG9-76 and 15N-PcrG9-76-GB1-6His titrated 
with increasing amounts of PcrV25-294.  Six samples were prepared in NMR buffer with 
0.13 mM 15N-PcrG9-76 and varying PcrV25-294 (0.00, 0.04, 0.08, 0.16, 0.32, and 0.65 mM).  
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Four samples were prepared in NMR buffer with 0.39 mM 15N-PcrG9-76-GB1-His6 and 
varying PcrV25-294 (0.00, 0.20, 0.40, and 0.80 mM). 
 
Circular Dichroism Spectroscopy 
 
Full length PcrG and the truncated construct, PcrG9-76, were cleaved by TEV 
protease, concentrated to 5.8 µM, and dialyzed in buffer (10 mM NaHPO4, 10 mM NaCl, 
pH 7.0) for all CD spectroscopy and thermal denaturation experiments.  Using a JASCO 
J-815 Spectropolarimeter, CD spectra were collected in triplicate from 195 to 260 nm at 
50nm/min.  Thermal denaturation curves were observed at 222 nm from 20-80°C at a 
ramp rate of 30°C/h.  Control curves from buffer alone were subtracted in both 
experiments. 
 
Surface Plasmon Resonance Spectroscopy 
 
Apparent dissociation constants (KD) between PcrGFL or PcrG9-76 and PcrV25-294 
were measured by means of surface plasmon resonance (SPR) using a Biacore 3000 
instrument (Biacore, Uppsala, Sweden).  A 1:1 (v/v) mixture of 400 mM 1-ethyl-3- (3-
dimethylaminopropyl) carbodiimide (EDC) (Sigma) and 100 mM N-hydroxysuccinimide 
(NHS) (Sigma) was prepared and immediately injected into two flow cells of a CM5 chip 
to activate the carboxymethylated dextran surface.  Lyophilized anti-polyhistidine 
antibodies (R&D Systems, Inc.) were resuspended to 25 µg/mL in immobilization buffer 
(10 mM sodium acetate, pH 5.0) and injected into the 2 activated flow cells for amine 
coupling.  Remaining uncoupled surfaces were inactivated by injection of blocking buffer 
(1 M ethanolamine, pH 8.5) (Sigma).  Activation, coupling, and blocking steps were 
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performed for 7 min at a flow rate of 10 µL/min resulting in anti-polyhistidine direct 
coupling of ~14,000 response units (RUs) in both flow cells. 
 Biacore assays were performed at 25°C using freshly prepared and degassed 
running buffer (10 mM HEPES, 150 mM NaCl, 0.005% (v/v) Surfactant P-20, pH 7.4).  
Unlabeled PcrGFL or PcrG9-76 (still fused to C-terminal GB1-His6 tag) was dialyzed 
overnight in running buffer and immobilized to the anti-polyhistidine coated surface of 
flow cell 2 by injection of 6-9 µL of 1 µg/mL protein at 10 µL/min.  Varying 
concentrations (2-32 nM) of the PcrV25-294 analyte (TEV cleaved and dialyzed overnight 
in running buffer) were then injected in both flow cells at 40 µL/min.  Immobilization of 
the ligand and binding of analyte was repeated for each PcrV25-294 concentration followed 
by surface regeneration using 20 µL pulses of regeneration buffer (10 mM glycine, pH 
2.0).  KD values were calculated using BIAevaluation 4.1 software only after subtracting 
the flow cell 1 sensorgram (control) from flow cell 2 to account for non-specific binding 
of analyte to the surface. 
 As an additional control, the above steps were repeated using the TEV cleavage 
GB1-His6 tag as the ligand immobilized to the anti-polyhistidine coated surface to verify 
that the fusion tag did not contribute to binding.  Tests for mass transfer effect were also 
performed to validate the selected analyte flow rate (40 µL/min).   
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RESULTS 
 
 
Defining a PcrG Domain for NMR Characterization 
 
LcrG is the most closely related homolog of PcrG and shares with it a 41% 
sequence identity (Figure 3-1).  Two unique LcrV binding domains on LcrG have been 
separately proposed by yeast two-hybrid studies12 and NMR chemical shift mapping 
(unpublished, Sukanya Chaudhury, University of Kansas)13.  Results of the yeast two-
hybrid study suggested that the LcrG N-terminus residues, from residues D7 to T40 
(corresponding to D10 to A42 in PcrG), are required for LcrV interaction, whereas results 
from NMR suggested the same for residues G50 to R73 (A53 to S76 in PcrG) (Figure 3-
1).  Each of these suggested binding domains include regions that are highly conserved 
between LcrG and PcrG.  While in vivo substitutions of PcrG for LcrG in Yersinia pestis 
have been unable to transcomplement normal T3SS regulation, both proteins bind 
LcrV.12  Thus, PcrG likely maintains the LcrG binding motif for its respective adaptor 
protein.  Initial NMR spectra, aiming to identify the residues of PcrG interacting with 
PcrV, used 15N-labeled PcrGFL and resulted in very poor quality data (Figure 3-3a).  
Using several different secondary structure prediction servers, including ITASSER, DSC, 
MLRC, and PHD, it became clear that both termini of PcrG consist of random coils 
(Figure 3-2).  In order to include the structured domains of PcrG while maintaining 
hydrophilic terminal residues for solubility, a PcrG truncation was subcloned with 
residues 9 -76 fused to a C-terminal His6-tagged GB1 domain.  This truncation also 
retains the regions of PcrG homologous to previously proposed adaptor protein binding 
domains in LcrG.  
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Figure 3-1.  Sequence alignment of a protein BLAST with PcrG (Swiss-Prot ID: 
Q9I326_PSEAE) as the query sequence.   Blast results were aligned with the query using 
ClustalW (Thompson, J. D., Higgins, D. G., and Gibson, T. J. Nucleic Acids Res. 22, 
4673, 1994) and the figure was made using ESPript (Gouet, P., Courcelle, E., Stuart, D. 
I., and Metoz, F. Bioinformatics 15, 305, 1999).  The red and blue lines denote regions 
homologous to reported LcrV binding domains on LcrG using yeast two-hybrid assays12 
and NMR chemical shift mapping13, respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 3-2.  Secondary structure predictions for PcrG (Swiss-Prot ID: Q9I326) based on 
calculations from ITASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER) as well as 
DSC, MLRC, and PHD (http://npsa-pbil.ibcp.fr/cgibin/npsa_automat.pl?page=/NP-
SA/npsa_seccons.html).  Residues predicted to exist as part of a random coil or α-helix 
are denoted with letter “C” or “H”, respectively. 
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Protein Expression and Purification 
 
Full length PcrG and truncated PcrG9-76 were both overexpressed in E. coli and 
purified by Ni2+-affinity chromatography.  Purified fractions were then cleaved by a His6-
tagged TEV protease and products were loaded onto a Ni2+-affinity column to purify the 
cleaved PcrG.  Purified PcrGFL and PcrG9-76 were then concentrated to 0.8 mM and 0.7 
mM, respectively, and 2D 1H-15N HSQC spectra were collected (Figure 3-3).  While the 
full length protein provided a poor spectrum with broad and overlapped peaks, the  
PcrG9-76 truncation afforded a spectrum suitable for NMR characterization based on the 
presence of sharp and well resolved peaks.  A comparison between the circular dichroism 
(CD) spectra of the two proteins verifies that the PcrG9-76 truncation did not produce any 
appreciable changes to the secondary structure (Figure 3-4a).  In addition, thermal 
denaturation curves of PcrGFL and PcrG9-76 have no clear inflection points, indicating that 
neither construct contains a folded core. 
 
 
Figure 3-3.  2D 1H-15N HSQC spectrum of (A) PcrGFL and (B) truncated PcrG9-76. 
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Figure 3-4.  (A) CD spectra acquired at 25°C of PcrGFL and PcrG9-76 showing that the 
proteins are composed partially of α-helices and partially of random coils. (B) CD 
thermal denaturation plots of PcrGFL and PcrG9-76 lack inflection points, suggesting the 
proteins do not have a core structured domain.  
 
 
NMR Assignment 
 
 The 2D 1H-15N HSQC spectrum of PcrG9-76 was assigned nearly to completion 
using 3D HNCACB (Figure 3-5a) and 3D HNCA (Figure 3-5b) experiments.  Examples 
of the carbon backbone connectivity are illustrated in Figure 3-5.  The backbone amides 
of 54 residues, or approximately 80.1% of the 67 non-proline residues of PcrG9-76 were 
successfully assigned as well as all 8 residues of the C-terminal cloning artifact 
GSENLYFQ (Figure 3-6).  The side chain peak of the single tryptophan, W37, was also 
assigned.  The remaining 13 non-proline residues that could not be assigned due to peak 
overlaps or peak broadening were Glu (9), Glu (28), Arg (29), Leu (32), Leu (33), Met 
(36), Leu (49), Leu (50), Phe (51), Arg (56), Glu (57), Glu (65), and Glu (66).  Secondary 
chemical shift data was calculated for the assigned residues of PcrG9-76 (Figure 3-7).  The 
data indicates that the protein contains three major α–helical regions with short 
interspersed residues that lack secondary structure.  This observation correlates well with 
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the CD data collected for PcrG9-76 (Figure 3-4).  The CD spectrum contains two minima 
with a 222/208-nm amplitude ratio of approximately 0.7 (indicative of a partially 
unfolded and partially α–helical protein).   
 
Figure 3-5.  Representative portions of the 3D (A) HNCACB and (B) HNCA spectra of 
15N, 13C-PcrG9-76 spanning residues L40 to A46 to illustrate the backbone connectivity 
identified for PcrG9-76 assignment.  The peaks of lower intensity in each strip belong to 
residue (i-1).   
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Figure 3-6.  Assigned 2D 1H-15N HSQC spectrum of PcrG9-76.  Residue names are 
indicated in blue next to their corresponding peaks. 
 
 
 
Figure 3-7.  The Cα secondary chemical shifts of PcrG9-76.  Contiguous regions with 
positive secondary chemical shifts are typical of α–helical regions.  
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NMR Titrations 
 
NMR chemical shift mapping was used to characterize the PcrG-PcrV interaction. 
Purified 15N-labeled PcrG9-76 was combined with increasing concentrations of PcrV25-294 
in NMR buffer and 2D 1H-15N HSQC spectra were acquired for each PcrV:PcrG molar 
concentration ratio (0.0, 0.25, 0.5, 1.0, 2.0 and 4.0).  The 2D 1H-15N HSQC spectra for 
each titration ratio were superimposed to determine the changes in the 2D 1H-15N HSQC 
of PcrG as it binds to PcrV (Figure 3-8a).  With the exception of only 8 of the 75 
backbone amide peaks, nearly all peaks showed significant reduction in intensity as the 
molar ratio of titration increased.  The 8 peaks that maintained constant intensity 
throughout the titration corresponded to cloning artifact residues G77, S78, E79, N80, 
Q84, and 3 unassigned residues. 
A second NMR titration was performed with purified 15N PcrG9-76-GB1-His6 
(His6-tagged GB1 domain was left intact with the initial purpose of aiding solubility) 
combined with increasing concentration of PcrV25-294.  2D 1H-15N HSQC spectra were 
acquired at each PcrV:PcrG molar concentration ratio (0.0, 0.5, 1.0, and 2.0) and then 
superimposed (Figure 3-8b).  A PcrV:PcrG molar ratio of 2.0 was sufficient for binding 
saturation.  While the PcrG9-76-GB1-His6 spectrum has not been assigned, it very closely 
resembles that of its TEV cleaved counterpart (Figure 3-8a) along with 65 additional 
peaks from the appended GB1-His6 tag.  As the concentration of PcrV25-294 increases, it is 
clear that the new GB1-His6 residues remain inert and that the same subset of PcrG9-76 
peaks reduce in intensity as seen in the first titration.   
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Figure 3-8.  (A) Six overlaid 2D 1H-15N HSQC spectra of PcrG9-76 with increasing ratios 
of PcrV25-294.  Assigned backbone amide peaks that remained unperturbed by the titration 
are labeled.  (B) Four overlaid 2D 1H-15N HSQC spectra PcrG9-76-GB1-His6 with 
increasing ratios of PcrV25-294. 
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Surface Plasmon Resonance Spectroscopy 
 
Surface plasmon resonance (SPR) was used to evaluate the binding affinity and 
binding kinetics between PcrV25-294 and PcrG (full length and 9-76).  PcrG constructs 
were fused to C-terminal GB1-His6 tags to facilitate immobilization to anti-His6 antibody 
coated CM5 flow cells.  Injecting of PcrV25-294 into flow cells with immobilized PcrG 
produced a clear binding response that increased proportionally with increasing analyte 
concentration.  Using BIAevaluation 4.1 software, data for the interaction between 
PcrV25-294 and full length PcrG was best fit to a 1:1 Langmuir model (χ2 = 0.314) (Figure 
3-9a).  The KD for this interaction was calculated to be 2.65 × 10-8 M (26.5 nM).  This 
high affinity binding is very similar to that previously described by Nanao et. al9 in which 
SPR was used to evaluate binding between full length proteins, PcrG and PcrV.  Thus, 
the N-terminal 24-residue truncation of PcrV has little effect on the interaction.  The 
binding also occurred with rapid kinetics, as previously described9, with ka = 5.62 × 105 
M-1s-1 and kd = 1.53 × 10-2 s-1. 
The truncations made in PcrG9-76 did not appear to have a significant effect in its 
PcrV-binding capacity.  In fact, the sensorgram for PcrV25-294 binding to immobilized 
PcrG9-76-GB1-His6 was fit to a 1:1 Langmuir model (χ2 = 2.53) and the calculated 
binding affinity was slightly stronger than that for PcrGFL (KD = 2.37 × 10-8 M or 23.7 
nM) (Figure 3-9b).  Also, the binding kinetics were found to be more rapid than seen for 
PcrGFL, though less than an order of magnitude, with ka = 1.02 × 106 M-1s-1 and kd = 2.42 
× 10-2 s-1.  These minimal changes in binding suggest that truncated PcrG9-76 retains the 
PcrV-interaction domain. 
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To account for possible interference of the GB1-His6 tag with the PcrG-PcrV 
interaction, a control sensorgram was collected with identical conditions from the 
previous experiment, but with GB1-His6 as the ligand (Figure 3-10a).  The binding 
response to PcrV25-294 was insignificant and did not increase with respect to PcrV25-294 
concentration.  Therefore, the appended GB1-His6 tag remained inert in the interaction.  
As an additional control, a test for mass transfer effect was performed by varying the 
PcrV25-294 analyte flow rate from 5-80 µl/min over immobilized PcrGFL-GB1-His6 
(Figure 3-10b).  No resulting differences were observed in the association phase of these 
sensorgrams, which confirms the lack of a mass transfer effect and validates the selected 
analyte flow rate of 40 µl/min.        
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Figure 3-9.  SPR sensorgrams for PcrV25-294 binding to PcrGFL and PcrG9-76.  A serial set 
of PcrV25-294 concentrations (2-32 nM) were injected at 40 µl/min for 3 min over 
immobilized (A) PcrGFL-GB1-His6 (200 RU); (B) PcrG9-76-GB1-His6 (104 RU).  Non-
specific binding of the analyte to the anti-His6 antibody coated surface and the bulk effect 
from the buffer were determined from flow cell 1 and subtracted from the raw data. 
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Figure 3-10.  (A) SPR sensorgram control for PcrV25-294 binding to a GB1-His6 fusion 
tag.  A serial set of PcrV25-294 concentrations (2-32 nM) were injected at 40  µl/min for 3 
min over immobilized GB1-His6 (108 RU). (B) Injection of 8 nM PcrV25-294 at varying 
flow rates over immobilized PcrGFL-GB1-His6 to test for mass transfer effect. 
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DISCUSSION 
 
Recent results have pointed to the essential role of PcrG in control of effector 
protein secretion in Pseudomonas aeruginosa as well as to its probable role as an export 
chaperone of the tip protein, PcrV.7; 8  Direct binding between PcrG and PcrV has been 
demonstrated9; 10, however, a clear PcrV binding region on PcrG has yet to be identified.  
The closest homolog of PcrG, LcrG of the Yersinia T3SS, has also been attributed with a 
role in secretion regulation and has been shown to interact with its respective tip protein, 
LcrV.11  However, the mechanisms by which PcrG and LcrG mediate secretion regulation 
in their respective type III secretion systems differ substantially.8; 12  The aim of this 
study was to identify whether the PcrV binding region on PcrG is conserved with the 
previously reported tip protein binding on its close homolog, LcrG.  Instead, NMR 
experiments indicate that PcrV induces a global change in PcrG structure that likely 
results as a combination of PcrV-binding interactions and binding-induced 
conformational changes.  In addition, the first experimentally derived information on 
sequence specific secondary structure identified the regions of PcrG that adopt either α–
helical or random coil conformation.           
Based on sequence conservation, predicted random coil domains, and previously 
proposed tip protein binding domains in LcrG, a suitable PcrG truncation was constructed 
for NMR interaction studies.  Approximately 80.1% of the PcrG9-76 2D 1H-15N HSQC 
spectrum was successfully assigned by use of 3D NMR experiments.  Assignment was 
followed by a titration of 15N-PcrG9-76 with PcrV25-294, which resulted in peak intensity 
reduction of 67 of the 75 backbone amide peaks.  Notably, only 3 of the 8 residues that 
remained inert in the interaction are part of the PcrG9-76 sequence and the remaining 5 
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belong to the C-terminal cloning artifact.  While a majority of the peaks disappeared 
upon binding saturation with PcrV25-294, this was not accompanied by the reappearance of 
new peaks, which is common for interactions in the intermediate exchange NMR time 
scale.  For this reason, no structural information can be extracted with regard to the 
bound-state of PcrG.  However, the observation that ~89.3% of the PcrG9-76 peaks are 
reduced suggests that PcrV binding induces radical changes in PcrG structure.  This is not 
unprecedented for natively unstructured proteins, which in most observed cases undergo 
binding induced folding transition.23  The notion of a global structural transition is also 
supported by previous computational predictions that suggest LcrV interacts with LcrG 
via an LcrG coiled-coil domain.11; 12      
In addition to identifying LcrV-interacting residues, NMR assignment of PcrG 
also elucidated the protein’s sequence specific secondary structure.  Secondary chemical 
shift data indicates roughly three stretches of α-helical regions (residues 10-26, 29-41, 
and 53-76) separated by short unstructured regions.  While this data and the NMR 
titration data were limited by the use of truncated PcrG, the purported PcrV binding 
domain12; 13 was retained.  The validity of this truncation study is also supported by CD 
and SPR data.  Circular dichroism showed that the PcrGFL and PcrG9-76 spectra overlaid 
very closely and therefore maintained similar ratios of secondary structure composition.  
Results from the SPR binding interaction verified that the PcrG truncation sustained 
relatively unchanged binding affinity for PcrV25-294 as well as similar binding kinetics.  In 
fact, the binding affinity was slightly higher than that of PcrGFL, which might be 
attributed to the removal of non-participating residues that may otherwise reduce binding 
accessibility.   
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Despite the experimental advantages provided by truncating the 8 N-terminal 
residues and C-terminal 22 residues of PcrG, this prevented characterization of structure 
or binding within these regions.  The study was also limited in that chemical shift 
mapping cannot decipher between PcrG residues directly binding PcrV and those 
involved in binding induced conformational change.  Future studies might consider 
alternative methods to identify interacting residues of the full length protein, such as a 
yeast two-hybrid study (successfully applied in the Yersinia system12).    
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Chapter 4: Discussion of Type III Secretion System Projects	  
	  
	  
	   The type III secretion system (T3SS) is a complex set of regulatory and structural 
protein machinery common to many Gram-negative bacteria for virulence.1 Many of 
these bacterial species are human pathogens and cause a variety of infectious diseases.2  
These resulting diseases can be fatal and range from chronic infections of the lungs in 
cystic fibrosis patients from Pseudomonas aeruginosa infection to gastroenteritis from 
Salmonella typhimurium.1; 3  Each of these species uses the T3SS to deliver bacterial 
effector proteins into the host cell cytosol in order to manipulate normal host cell 
functions.1; 4  The purpose of these host cell alterations varies widely between bacterial 
species, including prevention of phagocytosis, evasion of host immune response, or even 
bacterial intracellularization.4  This variation in consequences for the host can largely be 
attributed to the many unique effector proteins between species (more than 100 have been 
identified4), however, the proteins components of the type III secretion apparatus (T3SA) 
used to transfer these effectors are both structurally and functionally conserved.5  As 
there are still gaps in the current knowledge of how some of these T3SS proteins interact 
to regulate T3SA assembly and effector secretion, both structural and functional studies 
of these proteins are essential.  In the work presented in this thesis, NMR studies and 
biophysical methods were used to characterize the interactions of T3SS tip proteins of S. 
typhimurium and P. aeruginosa with previously identified binding partners implicated in 
secretion control. 
The binding of bile salts to the Shigella tip protein, IpaD, was recently suggested 
to play a role in activating the Shigella T3SS by inducing the secretion of the translocon 
protein, IpaB.6  This is significant in that bile salts are a major component of bile and are 
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present in the stomach and intestines where Shigella infects humans.7  Salmonella are 
another enteric pathogen and the Salmonella tip protein, SipD, was also recently shown 
to bind bile salts.8  However, Salmonella exhibit a response opposite to that of Shigella, 
whereby growth in the presence of bile reduces invasiveness.9; 10  This difference in 
response to bile salts is poorly understood.   
After finding that SipD39-343 provides a high quality NMR spectrum, SipD39-343 
was titrated with three different prevalent bile salts.  Each of the bile salts perturbed a 
nearly identical set of SipD residues that primarily cluster in a loop between the N-
terminal two-helix bundle and the central coiled-coil.  While several other residues were 
also perturbed, the major cluster of interacting residues lies on the opposite side of the 
central coiled-coil from where the structurally similar tip protein, IpaD, was predicted to 
bind bile salts by computer simulated docking.8   Additional testing to verify the 
interacting residues of SipD was attempted using isothermal calorimetry (ITC) and a 
Salmonella invasion assay.  However, ITC was limited by the low CMC of the bile salts 
and results of the invasion assay were inconclusive.  In the invasion assay, only single 
point mutations of SipD were introduced and were potentially not severe enough to 
disrupt bile salt binding.  Based on the NMR titration data, it is proposed that the 
alternative bile salt binding sites for the two tip proteins may account for the differing 
bile salt responses between the two species.  The reason for the differing responses 
remains unclear, however it may correlate to different spatial preferences in the gut for 
invasion.  The tip protein-bile salt interaction would serve as a logical system for spatial 
orientation within the gut since 1) the tip proteins of both species have been shown to 
localize to the bacterial surface before cell contact11; 12, 2) the tip proteins are the only 
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identified direct binding partners of bile salts, and 3) both species are exposed to bile near 
their target tissue for invasion, and 4) reabsorption and recycling of bile salts in the 
intestines leads to a concentration gradient.7    
The tip protein, PcrV, of Pseudomonas aeruginosa and its proposed cytoplasmic 
chaperone, PcrG, have been clearly demonstrated with roles in effector secretion 
control.13; 14; 15  For this species, secretion is normally initiated by cell contact or 
depletion of Ca2+.16  However, deletions of either PcrG or PcrV lead to secretion in the 
absence of these events.15  PcrG and PcrV directly interact17; 18 and PcrG has been shown 
to facilitate PcrV secretion.15   
For further investigation, NMR was used to characterize this interaction using a 
PcrG truncation (residues 9-76) that provided an excellent NMR spectrum.  The 
truncation was demonstrated to have little effect on the PcrG secondary or tertiary 
structure using circular dichroism (CD) and thermal denaturation.  Also, surface plasmon 
resonance (SPR) verified minimal changes to the PcrG-PcrV binding affinity and binding 
kinetics when PcrG is truncated.  Approximately 80.1% of the PcrG9-76 HSQC spectrum 
was successfully assigned and these assignments were subsequently used for secondary 
chemical shift calculations and analysis of PcrV titrations.  While PcrG had been 
previously observed to have partial α–helical structure when free in solution17, secondary 
chemical shift analysis provided the first experimentally derived sequence specific 
structural information and identified approximately 3 major α–helical regions with 
flanking random coils.  NMR titrations were performed to elucidate whether the 
interaction with PcrV results in a PcrG binding-induced folding event, which is common 
for natively unfolded proteins19, and to identify the interacting residues of PcrG.  
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Titration with PcrV resulted in peak reductions of nearly all PcrG residues.  One 
interpretation of this change, though unlikely, is that nearly all of the PcrG9-76 residues 
directly bind PcrV.   Such a large surface area for binding would be supported by the high 
binding affinity identified by SPR.  However, if PcrG retains the α–helical regions from 
its unbound structure (moreover, if it adopts tertiary structure upon binding), it is less 
plausible that all PcrG residues could constitute a single binding surface.  Instead it is 
proposed that the global effect on PcrG residues from PcrV binding results as a 
combination of direct residue contacts with PcrV and binding-induced conformational 
changes in PcrG.  Since PcrV binding leads to a global change in the PcrG HSQC 
spectra, the utility of the NMR titration is limited.  An alternate approach might be a 
yeast two-hybrid study, which has been used to identify the tip protein binding region of 
the close homolog of PcrG in Yersinia pestis, LcrG.  Identification of these interacting 
residues will be critical in understanding the mechanism facilitating PcrV secretion. 
In summary, the T3SS studies presented in this thesis have contributed to the 
further understanding of secretion control mediated by tip proteins and their binding 
partners.  The study of the PcrG-PcrV interaction elucidated a step critical to 
Pseudomonas aeruginosa tip protein secretion and the study of the SipD interaction with 
bile salts identified a binding site that may account for the differing responses of 
Salmonella and Shigella to bile.  Characterization of these interactions has potential 
towards facilitating the intelligent design of novel antibacterial agents that might disrupt 
proper assembly and regulation of the type III secretion system. 
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Addendum:  NMR Characterization of the Xenopus laevis PARP1-
PIASy Interaction 
 
 
INTRODUCTION 
 
Post-translational modification by SUMO (small ubiquitin-related modifier) has 
been studied for nearly 14 years, over which time many SUMOylation targets and 
functions have been identified.1  SUMO is found in all eukaryotic cells and SUMOylation 
has been discovered to have roles in altering the stability, activity, localization, and 
interactions of its target proteins.2  The process of SUMOylation entails three important 
steps carried out by three intermediate enzymes (E1 activating enzymes, E2 conjugating 
enzymes, and E3 ligases).1; 2  While the same E1 and E2 enzymes, respectively 
Aos1/Uba2 and Ubc9 in Xenopus laevis, participate in all SUMOylation, many unique E3 
enzymes have been identified and are recognized for mediating target specific SUMO 
conjugation.3  One such enzyme, from the family of protein inhibitors of activated STAT 
(PIAS), is PIASy and has been shown to mediate critical mitotic chromosomal protein 
SUMOylation for efficient chromatin separation during anaphase.4  More recently, Ryu 
et. al (5) identified a novel mitotic SUMOylation substrate, PARP1.  
Poly(ADP-ribose) polymerases (PARP) catalyze post-translational modification 
by covalently attaching chains of poly(ADP-ribose) to substrates (known as PARylation).  
PARylation is closely tied to proper mitotic function.  PARP1 localizes to condensed 
chromatin with particular concentration near the centromere5 and its inhibition has been 
demonstrated to prevent mitotic spindle formation6.  Ryu et. al (5) found PARP1 
SUMOylation significantly reduces PARylation of mitotic chromatin.  The same study 
discovered that PARP1 SUMOylation in Xenopus egg extracts required PIASy and that 
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this E3 ligase both enhanced SUMOylation efficiency and promoted modification site 
specificity.5  Together, these findings suggest that PIASy-dependent SUMOylation of 
PARP1 may have a critical role in mitotic regulation. 
 In order for PIASy to mediate SUMOylation, a 4-protein complex including 
Ubc9-SUMO-2/3, PIASy, and a target protein is formed to facilitate isopeptide bond 
formation between SUMO and a particular lysine residue on the target.  While domain 
analysis of one E3 ligase, Siz1, has recently elucidated this conjugation step in yeast7, 
little structural information is available for the vertebrate system.  In this study, NMR 
titrations were used in an attempt to identify the interacting residues of Xenopus laevis 
PARP1 and PIASy.  While PARP1 potentially contains more than one PIASy binding 
domain, PARP1375-650 was identified as a minimum domain for E3-dependent 
SUMOylation (unpublished, Gada Al-Ani, University of Kansas).  NMR titration of a 
fragment within this domain, PARP1503-650, indicated that approximately 9 PARP1 
residues have contacts with PIASy.  Since the titration was performed in the absence of 
Ubc9-SUMO-2/3 or other SUMOylation machinery, the results suggest that PARP1 
interacts with PIASy prior to formation of the 4-protein complex of the SUMO 
conjugation step.  Further investigation will be required to determine if other portions of 
the minimal domain for PIASy-dependent sumoylation also interact and to identify these 
residues. 
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MATERIALS AND METHODS 
 
Protein Expression and Purification 
  
PARP1 fragments (residues 375-650, 375-525, 503-650, and 514-639) were PCR 
amplified from Xenopus laevis cDNA and subsequently subcloned into pET-29a or into 
pET-21a (as an N-terminal or C-terminal fusion to a TEV recognition sequence and His6-
tagged GB1 domain as described above).  All constructs were expressed in BL21(DE3) 
DNAY cells using LB media or 15N M9 minimal media, as described above.  Cells were 
harvested by centrifugation, resuspended in binding buffer (500 mM NaCl, 20 mM Tris-
HCl, 5mM imidazole, pH 8.0), and lysed by sonication in the presence of 10 mg 
phenylmethyl sulfonyl fluoride (PMSF).  The lysate was centrifuged again to remove cell 
debris, supernatant was loaded onto a Ni2+-affinity column (Sigma), and elutes were 
pooled.  PARP1 samples expressed from the pET-21a plasmid were used in the NMR 
studies with and without TEV proteolysis (which removed the His6-tagged GB1 domain). 
Samples to be digested with protease followed the first Ni2+ affinity purification with 
addition of TEV protease and overnight dialysis as described8.  After TEV proteolysis, 
protein samples were loaded onto a Ni2+ affinity column and the cleaved PARP1 was 
collected in the flow-through fractions.  
Unlabeled PIASyFL protein samples for NMR titration of PARP1 were provided 
by Dr. Azuma (University of Kansas).  All proteins samples for PARP1 and PIASy were 
concentrated using Amicon Ultra 3K (Millipore) and concentration was determined using 
absorbance at 280 nm. 
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NMR Spectroscopy 
 
NMR data were collected at 25°C using Bruker Avance 800 MHz equipped with a 
cryoprobe, processed with NMRPipe9, and analyzed using NMRView10. All protein 
samples were dialyzed overnight in NMR buffer (10-150 mM NaHPO4, 10 mM NaCl, 
10% (v/v) D2O, pH 7.0) prior to data collection.  15N-PARP1375-525 (~40 µM) and 15N-
PARP1503-650 (~30 µM) were used to collect initial 2D 1H-15N HSQC11 spectra.  After 
subcloning PARP1503-650 into pET-21a, two additional 2D 1H-15N HSQC11 spectra were 
acquired using TEV cleaved samples (~90 µM each).  These samples differed by the 
cloning artifact that remained after TEV proteolysis (an N-terminal “GHM” or C-
terminal “GSENLYFQ”).  The sample with the N-terminal “GHM” also retained a 26 
residue C-terminal tail as a cloning artifact.  The final 2D 1H-15N HSQC11 spectrum 
collected used 15N-PARP1514-639 (~80 µM) with the N-terminal cloning artifact “GHM”. 
For NMR chemical shift mapping, 2D 1H-15N HSQC11 were collected using 15N-
PARP1503-650-GSENLYFQ or 15N-GHM-PARP1503-650 (+26 C-terminal residues) titrated 
with increasing amounts of PIASyFL as follows:  3 samples of 75 µM 15N-PARP1503-650-
GSENLYFQ were prepared in NMR buffer (150 mM NaCl, 10 mM NaCl, 10% (v/v) 
D20, pH 7.0) with increasing concentrations of PARP1FL (0, 37.5, and 75 µM); 3 samples 
of 45 mM 15N-GHM-PARP1503-650 (+26 C-terminal residues) were prepared in NMR 
buffer with increasing concentrations of PARP1FL (0, 45, and 116 µM).   
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RESULTS 
 
PARP1 Expression and Solubility 
 
The PARP1 fragments used herein were based on previous in vitro SUMOylation 
studies that identified the minimum domain required for PIASy-mediated modification by 
SUMO-2/3 (Gada Al-Ani, University of Kansas).  This minimum domain, PARP1375-650, 
was then further divided to more narrowly identify PIASy interaction surfaces by NMR 
(Figure A-1). 
 NMR experiments were initially performed using PARP1375-525 and PARP1503-650.   
While each of the PARP1 fragments illustrated in Figure A-1 were successfully 
expressed and purified, overnight dialysis in a standard low salt NMR buffer (10 mM 
NaCl, 10 mM NaHPO4, pH 7.0) led to significant precipitation.  PARP1375-650 and 
PARP1503-650 completely fell out of solution and PARP1375-525 was only stable at ~40 µM.  
Increasing the ionic strength of the buffer to 50 mM permit initial 2D 1H 15N-HSQC data 
acquisition for the two smaller fragments (data not shown).  The resulting HSQC 
spectrum of PARP1375-525 exhibited highly overlapped peaks in a narrow proton range.  
On the other hand, PARP503-650 provided a well-dispersed spectrum, but was of too poor 
quality for resonance assignments. 
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Figure A-1.  PARP1 fragments derived from Xenopus laevis PARP1FL for NMR 
analysis.  The lysine that forms an isopeptide bond with SUMO2/3 is indicated with an 
asterisk.   
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To facilitate solubilization, PARP1503-650 was subcloned into pET-21a vectors 
resulting in an N-terminal or C-terminal fusion to GB1, the highly soluble G1 domain of 
Streptococcus protein G.  These constructs remained much more stable in solution, but 
the GB1 fusion also led to expression as a dimer.  Subsequent removal of the GB1 
domain by TEV proteolysis eliminated dimerization.  While TEV cleavage negated the 
purpose of the new constructs, it provided the proteins with smaller cloning artifacts and 
maintained higher solubility than the original constructs.  Several NMR buffer conditions 
were tested to maximize saturation concentration (Table A-1). 
  
 
 
 
 
 
 
Table A-1.  Solubility testing for PARP1503-650-GSENLYFQ including variable pH and 
buffer choice.  Saturation concentration refers to concentration measurements taken after 
samples ceased to precipitate.  An asterisk indicates the chosen buffer. 
 
 
 
 
 
 
 
 
 
 
Buffer pH Saturation Concentration (mM)
10 mM NaHPO4, 50 mM NaCl, 5% (v/v) D2O 5.5 0.0845
10 mM NaHPO4, 50 mM NaCl, 5% (v/v) D20 6.0 0.0909
10 mM NaHPO4, 50 mM NaCl, 5% (v/v) D20 6.5 0.0891
10 mM NaHPO4, 50 mM NaCl, 5% (v/v) D20 7.0 0.0925
10 mM NaHPO4, 50 mM NaCl, 5% (v/v) D20 7.5 0.0951
*
5 mM HEPES, 50 mM NaCl, 5% (v/v) D20
5 mM Tris/HCl, 50 mM NaCl, 5% (v/v) D20
5 mM HEPES, 50 mM NaCl, 5% (v/v) D20
7.5
7.5
6.8
0.0630
0.0800
0.0610
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NMR Titrations 
 
 NMR chemical shift mapping was used to identify residues of PARP1 that 
interact with PIASy during PIASy-mediated PARP1 SUMOylation.  15N-PARP1503-650-
GSENLFQ was prepared in the chosen NMR buffer (Table A-1) and provided an 
excellent initial spectrum (Figure A-2a).  NMR titrations were then performed by 
preparing 15N-PARP1503-650-GSENLYFQ with increasing concentrations of PIASyFL and 
2D 1H-15N HSQC were acquired for each PIASy:PARP1 concentration ratio (0.0, 0.5, 
and 1.0) (Figure A-2b).  Approximately 9 different PARP1503-650 peaks show clear 
reduction in peak intensity as the titration ratio increased (indicated by arrows in Figure 
A-2b).  This is characteristic of interactions in the slow-exchange NMR time scale.  
Despite the observation that 9 residues in this fragment interact with PIASy, residue 
assignments were not possible due to the high concentration requirement for 3D NMR 
experiments. 
 In spite of the 26-residue C-terminal extension of the GHM-PARP1503-650 
construct, NMR titrations of this construct with PIASyFL still proved useful in supporting 
titration results shown in Figure A-2b.  In addition to the appearance of new peaks, many 
chemical shift changes in the 2D 1H-15N HSQC indicate that the lengthened C-terminus 
made small changes in protein folding (Figure A-3a).  Despite these changes, 6 of the 
peaks affected by PIASy correspond to those of the previous titration (Figure A-3b).  
These residues have not yet been assigned, but these consistent results support the 
specificity of the interaction. 
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Figure A-2.  (A) 2D 1H-15N HSQC spectrum of free 15N-PARP1503-650-GSENLYFQ.   
(B) Three overlaid 2D 1H-15N HSQC spectra of 15N-PARP1503-650-GSENLYFQ titrated 
with PIASyFL.  Spectra are color coded according to the protein molar ratio.  Arrows 
denote peaks exhibiting intensity reduction. 
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Figure A-3.  (A) 2D 1H-15N HSQC spectra of free 15N-GHM-PARP1503-650 (with 
additional 26 residue C-terminal tail) in comparison with 15N-PARP503-650-GSENLYFQ.  
(B) Three overlaid 2D 1H-15N HSQC spectra of 15N-GHM-PARP1503-650 (with additional 
26-residue C-terminal tail) titrated with PIASyFL. Arrows denote peaks exhibiting 
intensity reduction and blue arrows denote peaks corresponding to those reduced in 
Figure A-2b. 
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 An additional attempt was made to attain a PARP1 fragment stable enough in 
NMR solution for 3D experimentation.  The structure of human PARP1 (residues 518-
643) was previously solved by NMR techniques and has been deposited at the Protein 
Data Bank with accession code 2CR9.12  This fragment closely corresponds to the 
Xenopus laevis PARP1503-650 constructs tested in this work and a sequence alignment 
confirmed an 81% sequence identity with Xenopus laevis residues 514-639 (Figure A-4).   
This fragment was expressed with an N-terminal GB1 tag, cleaved with TEV protease, 
and dialyzed overnight in the NMR buffer chosen by Nagashima et. al12 (20 mM 
Tris/HCl, 100 mM NaCl, 1mM DTT, 0.02% (v/v) NaN3, 10% (v/v) D20, pH 7.0).  The 
sample initially maintained a high concentration (~0.8 mM) and 2D 1H-15N HSQC data 
were acquired (Figure A-5).  The resulting spectrum was well dispersed with little 
overlap, however, the sample slowly precipitated to ~80 µM over the course of 5 days.  
3D data were not collected. 
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Figure A-4.  Alignment of the Xenopus laevis (Swiss Prot ID: Q2NLA7) and human 
(Swiss Prot ID: P09874) PARP1 DNA sequences corresponding to the published 
structure of PARP1 fragment 2CR9.  Blue letters indicate cloning artifact from 2CR9 (not 
part of wild-type human parp1).  
 
 
 
 
 
 
 
Figure A-5.  2D 1H-15N HSQC spectrum of 15N-GHM-PARP1514-639. 
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DISCUSSION 
 
The major finding of the NMR experiments herein is that the E3 ligase, PIASy, 
interacts with PARP1 prior to formation of the 4-protein quaternary complex (SUMO, 
Ubc9, PIASy, and PARP1) involved in the SUMOylation conjugation step.  The 
identified interaction domain is located within residues 503-650 of X. laevis PARP1, 
which may or may not contain the entire interaction surface.  This conclusion is based on 
the PARP1-PIASy NMR titration where approximately 9 unidentified peaks within the 
15N-PARP1503-650-GSENLYFQ spectrum exhibited significant intensity reduction.  The 
interaction was observed in the absence of the Ubc9-SUMO-2/3 complex or other SUMO 
conjugation machinery.  Unfortunately, the low solubility of the PARP1 constructs used 
in the NMR titrations prevented the acquisition of the 3D NMR experiments needed for 
spectrum assignment.   
Recent work identified a larger PARP1 domain (residues 375-650) required for 
PIASy-dependent SUMOylation (Gada Al-Ani, University of Kansas) that includes the 
predominantly modified residue, lysine 482.5  Additional fragmentation of this domain 
(unpublished, Gada Al-Ani, University of Kansas) or conservative mutation5 of lysine 
482 has been shown to remove PIASy-dependent SUMOylation specificity for this site.  
Taking this into account, it is possible that the observed 9-residue interaction of PIASy 
with PARP1503-650 in this work would be altered with the addition of the PARP1 
minimum domain remainder.  However, analysis of this addition was not possible by 
means of NMR due to solubility limitations and the unstructured nature of PARP1 
residues 375-525.  In the case that the absence of PARP1 residues 375-502 altered the 
PIASy interaction domain specific for lysine 482 modification, the observed 9-residue 
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interaction may correlate to a secondary PIASy-interaction domain to mediate an 
alternate SUMOylation site.  PIASy has been shown to increase SUMOylation capacity 
of multiple PARP1 lysine residues, in addition to promoting residue specificity, which 
supports the likelihood of multiple PIASy-interaction domains on PARP1.5  The same 
theme has also been observed in yeast where Siz1 (PIASy paralogue) has been shown to 
mediate SUMOylation of multiple residues of a single target protein, PCNA.7   
In summary, the work presented here suggests that the PIASy E3 ligase 
independently associates with PARP1 prior to complex formation with Ubc9-SUMO-2/3.  
Future work may address folding and solubility restrictions by use of limited proteolysis 
and mass spectrometry to identify independently folded structural domains.  Solubility 
has proven to be a critical barrier that must be addressed both for quality NMR titrations 
of the minimum PARP1 domain and for assignment of those residues interacting with 
PIASy.  Identification of these residues will be essential in understanding the mechanism 
of PIASy-dependant SUMO conjugation. 
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